Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Urothelial Carcinoma Bladder · Bladder Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Project Manager) · RadOncCRU@PennMedicine.upenn.edu · 215-662-3790
Contact: Principal Investigator (John Christodouleas, MD)

Study leads

John Christodouleas, MD
Principal Investigator
University of Pennsylvania

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Advanced/Metastatic Solid Tumors · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · Irvine, United States

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

North Melbourne, Australia

Intervention of Bladder Cancer by CAR-T

Bladder Cancer · Urothelial Carcinoma Bladder

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Urothelial Carcinoma · Muscle-invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Orange, United States